The innate immune system in SLE: type I interferons and dendritic cells
2008 (English)In: Lupus, ISSN 0961-2033, E-ISSN 1477-0962, Vol. 17, no 5, 394-399 p.Article in journal (Refereed) Published
Patients with systemic lupus erythematosus (SLE) have an increased expression of type I interferon (IFN) regulated genes because of a continuous production of IFN-alpha. The cellular and molecular background to this IFN-alpha production has started to be elucidated during the last years, as well as the consequences for the innate and adaptive immune systems. Plasmacytoid dendritic cells (pDC) activated by immune complexes containing nucleic acids secrete type I IFN in SLE. Type I IFN causes differentiation of monocytes to myeloid-derived dendritic cell (mDC) and activation of autoreactive T and B cells. A new therapeutic option in patients with SLE is, therefore, inhibition of IFN-alpha, and recent data from a phase I clinical trial suggests that administration of neutralizing monoclonal antibodies against anti-IFN-alpha can ameliorate disease activity.
Place, publisher, year, edition, pages
2008. Vol. 17, no 5, 394-399 p.
Medical and Health Sciences
IdentifiersURN: urn:nbn:se:uu:diva-104082DOI: 10.1177/0961203308090020ISI: 000256126200009PubMedID: 18490415OAI: oai:DiVA.org:uu-104082DiVA: diva2:219321
Conference Information: 7th European Lupus Meeting
Amsterdam, NETHERLANDS, MAY 07-10, 2008 2009-05-272009-05-272011-03-23Bibliographically approved